Answers are grounded in this paper and cite their sources.
Abstract Introduction: Medicine is increasingly supported by software, with digital health technologies offering innovative ways to capture insights and drive therapies. Globally, medical device software must follow regulatory processes based on risk classification. The introduction of MDR represents a significant shift in risk-based qualification for Medical Devices in Europe, including classification Rule 11 for software, which has caused significant discussions among European regulators. Materials and Methods Three years after implementation, we conducted a systematic impact assessment of MDR classification Rule 11 for MDSW through a qualitative and quantitative analysis of over 2,000 software entries from the European Medical Device database, complemented by data from other public databases such as the German DiGa directory and mHealthBELGIUM. Results and Discussion Our results indicate a shift of the per-default classification of MDSW in Europe after the implementation of the MDR: while most of legacy software in EUDAMED falls in the lowest risk category as MDD Class I (53%), the situation reverses for the MDR conform entries with the most entries in Class IIa (55%). Analyzing the legacy MDD patient apps in Germany implies that three quarters will have to re-classify as MDR Class IIa at the end of the transition period in 2028. A comparison of the European and US regulatory landscapes, along with a systematic review of software features for Class I vs. Class IIa products, explains our findings and enables us to recommend a regulatory strategy for developing MDSW compliant with MDR Class I rules, ensuring fast access to the European market.
No takes yet. Share an insight, caveat, or question.
Schmitz et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: